Cited by 811Health Systems, Economic Evaluations, Quality of LifeEconomic and Environmental ValuationPharmaceutical Economics and Policy

The DOI matches its Crossref record; 183 of the 184 references it cites were found in a registry or an index.

Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report

Open access

Ramsey, Scott D., Willke, Richard J., Glick, Henry, Reed, Shelby D., Augustovski, Federico, Jonsson, Bengt, Briggs, Andrew, Sullivan, Sean D.·2015·Value in Health

DOI 10.1016/j.jval.2015.02.001

Open this paper in CoChat — free account

Abstract

Clinical trials evaluating medicines, medical devices, and procedures now commonly assess the economic value of these interventions. The growing number of prospective clinical/economic trials reflects both widespread interest in economic information for new technologies and the regulatory and reimbursement requirements of many countries that now consider evidence of economic value along with clinical efficacy. As decision makers increasingly demand evidence of economic value for health care interventions, conducting high-quality economic analyses alongside clinical studies is desirable because they broaden the scope of information available on a particular intervention, and can efficiently provide timely information with high internal and, when designed and analyzed properly, reasonable external validity. In 2005, ISPOR published the Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force report. ISPOR initiated an update of the report in 2014 to include the methodological developments over the last 9 years. This report provides updated recommendations reflecting advances in several areas related to trial design, selecting data elements, database design and management, analysis, and reporting of results. Task force members note that trials should be designed to evaluate effectiveness (rather than efficacy) when possible, should include clinical outcome measures, and should obtain health resource use and health state utilities directly from study subjects. Collection of economic data should be fully integrated into the study. An incremental analysis should be conducted with an intention-to-treat approach, complemented by relevant subgroup analyses. Uncertainty should be characterized. Articles should adhere to established standards for reporting results of cost-effectiveness analyses. Economic studies alongside trials are complementary to other evaluations (e.g., modeling studies) as information for decision makers who consider evidence of economic value along with clinical efficacy when making resource allocation decisions.

Integrity signals

Registry

Crossref · 10.1016/j.jval.2015.02.001

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,385
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
World Development indicators
Awais, A. (2015) · Data Archiving and Networked Services (DANS) · doi:10.17632/zcvgc6m58h.1 · Cited by 6,790
Statistical Analysis With Missing Data
Ghosh, S., Little, R. J. A., & Rubin, D. B. (1988) · Technometrics · doi:10.2307/1269814 · Cited by 4,730
Untitled work
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544

Flagged first, then by citations

Show all 184 references

1 of the 184 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Sullivan, 2001, Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial, Control Clin Trials, 22, 420, 10.1016/S0197-2456(01)00137-4 · DOI
Barber, 2000, Analysis of cost data in randomized trials: an application of the nonparametric bootstrap, Stat Med, 19, 3219, 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P · DOI

Sorted by citations

Items 101–200 of 810

Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina
Augustovski, F., Chaparro, M., Palacios, A., Shi, L., Beratarrechea, A. G., Irazola, V. E., Rubinstein, A., Mills, K. T., He, J., & Pichón-Rivière, A. (2018) · Value in Health · doi:10.1016/j.jval.2018.06.003 · Cited by 37
“Analyses were conducted following state-of-the-art methods of trial-based economic evaluation.(11) The Institutional Review Boards of Tulane University in the US and Hospital Italiano de Buenos Aires in Argentina approved the study protocol with the planned economic evaluation.”
BackgroundMethodSelf-citation
Fall prevention interventions in primary care to reduce fractures and falls in people aged 70 years and over: the PreFIT three-arm cluster RCT
Bruce, J., Hossain, A., Lall, R., Withers, E. J., Finnegan, S., Underwood, M. R., Ji, C., Bojke, C., Longo, R., Hulme, C. T., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25340 · Cited by 39
Operationalising treatment success in aphasia rehabilitation
Breitenstein, C., Hilari, K., Menahemi-Falkov, M., Rose, M. L., Wallace, S. J., Brady, M., Hillis, A. E., Kiran, S., Szaflarski, J. P., Tippett, D. C., et al. (2022) · Aphasiology · doi:10.1080/02687038.2021.2016594 · Cited by 37
“These analyses should adhere to established guidelines such as those laid out by the Task Force report of the International Society for Pharmacoeconomics and Outcomes Research Randomized Clinical Trials - Cost-Effectiveness Analysis (ISPOR RCT-CEA; Ramsey et al., 2015) or by the European Stroke Organisation Health Eco…”
Method
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-021-01426-6 · Cited by 41
Self-citation
Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST
Taylor, C. B., Thompson, K., Finfer, S. R., Higgins, A. M., Jan, S., Li, Q., Liu, B. C., & Myburgh, J. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30120-5 · Cited by 36
Head-to-Head Comparison of the Psychometric Properties of 3 Carer-Related Preference-Based Instruments
McCaffrey, N., Bucholc, J., Rand, S. E., Hoefman, R., Ugalde, A., Muldowney, A., Mihalopoulos, C., & Engel, L. (2020) · Value in Health · doi:10.1016/j.jval.2020.07.005 · Cited by 37
Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial
Christensen, K. D., Vassy, J. L., Phillips, K. A., Zawatsky, C. L. B., Azzariti, D. R., Lu, C. Y., Robinson, J. O., Lee, K., Douglas, M. P., Yeh, J. M., et al. (2018) · Genetics in Medicine · doi:10.1038/gim.2018.35 · Cited by 35
The cost-effectiveness of an internet intervention to facilitate mental health help-seeking by young adults: randomized controlled trial
Le, L. K.-D., Sanci, L., Chatterton, M. L., Kauer, S., Buhagiar, K., & Mihalopoulos, C. (2019) · Journal of Medical Internet Research · doi:10.2196/13065 · Cited by 35
“GLM using log link and gamma family was used for cost variables as recommended by the International Society for Pharmacoeconomics and Outcome Research guidelines [33].”
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%
Kuznik, A., Smare, C., Chen, C.-I., Venkatachalam, M., Keeping, S., Atsou, K., Xu, Y., Wilson, F. R., Guyot, P., Chan, K., et al. (2021) · Value in Health · doi:10.1016/j.jval.2021.08.009 · Cited by 36
Economic Costs of Delayed Diagnosis of Functional Motor Disorders: Preliminary Results From a Cohort of Patients of a Specialized Clinic
Tinazzi, M., Gandolfi, M., Landi, S., & Leardini, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.786126 · Cited by 35
“In the absence of a validated instrument for FMDs, we developed a customized questionnaire for collecting resource use data (26).”
Method
A cluster-randomized trial to reduce caesarean delivery rates in Quebec: cost-effectiveness analysis
Johri, M., Ng, E. S. W., Bermúdez‐Tamayo, C., Hoch, J. S., Ducruet, T., & Chaillet, N. (2017) · BMC Medicine · doi:10.1186/s12916-017-0859-8 · Cited by 34
“Costs and health outcomes were discounted at an annual rate of 0% due to the short (<1 year) period for results assessment [9, 10].”
Background
Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT
Gilson, R. J. C., Nugent, D., Bennett, K., Doré, C. J., Murray, M. L., Meadows, J., Haddow, L. J., Lacey, C. J., Sandmann, F., Jit, M., et al. (2020) · Health Technology Assessment · doi:10.3310/hta24470 · Cited by 34
Cost-Effectiveness of Robot-Assisted Radical Cystectomy vs Open Radical Cystectomy for Patients With Bladder Cancer
Dixon, S., Hill, H. R., Flight, L., Khetrapal, P., Ambler, G., Williams, N. R., Brew‐Graves, C., Kelly, J. D., Catto, J. W. F., iROC Study Team, et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.17255 · Cited by 33
Factors affecting adolescents’ participation in randomized controlled trials evaluating the effectiveness of healthcare interventions: the case of the STEPSTONES project
Saarijärvi, M., Wallin, L., Moons, P., Gyllensten, H., & Bratt, E. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-01088-7 · Cited by 32
Minimally Invasive Ponto Surgery compared to the linear incision technique without soft tissue reduction for bone conduction hearing implants: study protocol for a randomized controlled trial
Calon, T. G. A., van Hoof, M., van den Berge, H., de Bruijn, A. J. G., van Tongeren, J., Hof, J. R., Brunings, J. W., Jonhede, S., Anteunis, L. J. C., Janssen, A. M. L., et al. (2016) · Trials · doi:10.1186/s13063-016-1662-0 · Cited by 33
“The evaluation will be performed according to the standards and guidelines of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [50].”
Method
Clinical and Cost-Effectiveness of PSYCHOnlineTHERAPY: Study Protocol of a Multicenter Blended Outpatient Psychotherapy Cluster Randomized Controlled Trial for Patients With Depressive and Anxiety Disorders
Baumeister, H., Bauereiss, N., Zarski, A.-C., Braun, L., Buntrock, C., Hoherz, C., Idrees, A. R., Kraft, R., Meyer, P., Nguyen, T. B. D., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.660534 · Cited by 30
“Cost-effectiveness analyses will be reported according to Consolidated Health Economic Evaluation Reporting Standards statement [CHEERS; (41)] and the guidelines from the International Society for Pharmacoeconomics and Outcomes Research [ISPOR; (42)].”
Method
Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
Stopeck, A., Brufsky, A., Kennedy, L., Bhatta, S., Bhowmik, D., Buchanan, J., Despiégel, N., & Hechmati, G. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1651122 · Cited by 32
Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial
McMeekin, N., Geue, C., Briggs, A. H., Rombach, I., Li, H. K., Bejon, P., McNally, M., Atkins, B. L., Ferguson, J. Y., Scarborough, M., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15314.3 · Cited by 32
Self-citation
Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016
Shen, C., Tannenbaum, D., Horn, R. G., Rogers, J. E., Eng, C., Zhou, S., Johnson, B., Kopetz, S., Morris, V. K., Overman, M. J., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.13588 · Cited by 32
Economic evaluation of implementation science outcomes in low- and middle-income countries: a scoping review
Malhotra, A., Thompson, R. R., Kagoya, F., Masiye, F., Mbewe, P., Mosepele, M., Phiri, J., Sambo, J., Barker, A. R., Cameron, D., et al. (2022) · Implementation Science · doi:10.1186/s13012-022-01248-x · Cited by 33
“, annual re-trainings of personnel) [2, 3].”
A guided and unguided internet- and mobile-based intervention for chronic pain: health economic evaluation alongside a randomised controlled trial
Paganini, S., Lin, J., Kählke, F., Buntrock, C., Leiding, D., Ebert, D. D., & Baumeister, H. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023390 · Cited by 31
“25 The economic evaluation was conducted and reported in agreement with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement(26) and the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) guidelines.(27) In total, 302 participants were recruited from October 2014 to…”
The Pathways to Prevention program: nutrition as prevention for improved cancer outcomes
Hiatt, R. A., Clayton, M. F., Collins, K. K., Gold, H. T., Laiyemo, A. O., Truesdale, K. P., & Ritzwoller, D. P. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad079 · Cited by 32
“15 RCTs of nutritional interventions (69,70) that incorporate CEAs.”
Background
Economic Evaluation Associated With Clinical-Grade Mobile App–Based Digital Therapeutic Interventions: Systematic Review
Sapanel, Y., Tadeo, X., Brenna, C. T. A., Remus, A., Koerber, F., Cloutier, L. M., Tremblay, G., Blasiak, A., Hardesty, C. L., Yoong, J., et al. (2023) · Journal of Medical Internet Research · doi:10.2196/47094 · Cited by 31
The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study
Adamson, B. J. S., El-Sadr, W. M., Dimitrov, D., Gamble, T., Beauchamp, G. G., Carlson, J. J., Garrison, L. P., & Donnell, D. J. (2018) · Value in Health · doi:10.1016/j.jval.2018.09.001 · Cited by 31
“Our analytic methods and reporting follow guidelines from the Second Panel on Cost-Effectiveness in Health and Medicine [40,41], the International Society for Pharmacoeconomics and Outcomes Research - Society for Medical Decision Making Task Force on Good Research Practices for Randomized Clinical Trials Cost-Effectiv…”
Method
Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States
Sullivan, P. W., Li, Q., Bilir, S. P., Dang, J., Kavati, A., Yang, M., & Rajput, Y. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1660539 · Cited by 30
Closed-loop insulin delivery in pregnant women with type 1 diabetes (CRISTAL): a multicentre randomized controlled trial – study protocol
Beunen, K., Wilder, N. V., Ballaux, D., Vanhaverbeke, G., Taes, Y., Aers, X.-P., Nobels, F. R. E., Marlier, J., Lee, D. Y., Cuypers, J., et al. (2023) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-023-05481-0 · Cited by 31
Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases
Kim, H., Gill, B. S., Beriwal, S., Huq, M. S., Roberts, M. S., & Smith, K. J. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.02.045 · Cited by 32
The pharmacy care plan service: Evaluation and estimate of cost-effectiveness
Twigg, M. J., Wright, D. J., Barton, G., Kirkdale, C. L., & Thornley, T. (2018) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2018.03.062 · Cited by 31
Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer—the 5C study: a study protocol for a randomised controlled phase III trial
Puts, M. T. E., Hsu, T., Mariano, C. J., Monette, J., Brennenstuhl, S., Pitters, E., Ray, J., Wan-Chow-Wah, D., Kozlowski, N., Krzyzanowska, M. K., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024485 · Cited by 30
“Cost-effectiveness will be determined alongside the clinical trial following standard guidelines.(40) We will use two methods to collect data needed for the cost-effectiveness analyses: (a) EuroQol-5 dimensions with five levels (EQ-5D-5L)(41): the EQ-5D-5L is a well-validated, widely used, generic instrument that meas…”
Method
Team approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial
Mangin, D. A., Lamarche, L., Agarwal, G., Banh, H. L., Brown, N. D., Cassels, A., Colwill, K., Dolovich, L. R., Farrell, B. J., Garrison, S., et al. (2021) · Trials · doi:10.1186/s13063-021-05685-9 · Cited by 30
Assessing the Impact of EQ-5D Country-specific Value Sets on Cost-utility Outcomes
van Dongen, J. M., Ben, Â. J., Finch, A. P., Rossenaar, M. M. M., Biesheuvel-Leliefeld, K. E. M., Apeldoorn, A. T., Ostelo, R., van Tulder, M. W., van Marwijk, H., & Bosmans, J. E. (2020) · Medical Care · doi:10.1097/mlr.0000000000001417 · Cited by 29
Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy
McFerran, E., O’Mahony, J. F., Fallis, R., McVicar, D., Zauber, A. G., & Kee, F. (2017) · Epidemiologic Reviews · doi:10.1093/epirev/mxx002 · Cited by 29
“The use of a preference-weighted health-state classification system, such as EuroQol-5D (a descriptive system comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) (73), was not consistently reported.”
Method
Cost effectiveness review of text messaging, smartphone application, and website interventions targeting T2DM or hypertension
Willems, R. P., Annemans, L., Siopis, G., Moschonis, G., Vedanthan, R., Jung, J., Kwaśnicka, D., Oldenburg, B. F., D’Antonio, C., Girolami, S., et al. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00876-x · Cited by 30
“It is strongly recommended to consistently include a cost-effectiveness work package alongside clinical trials 55 .”
Background
Cost-Effectiveness Analysis of Nasal Continuous Positive Airway Pressure Versus Nasal High Flow Therapy as Primary Support for Infants Born Preterm
Huang, L., Roberts, C. T., Manley, B. J., Owen, L. S., Davis, P. G., & Dalziel, K. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.12.072 · Cited by 28
Meta‐analysis of the cost‐effectiveness of early versus delayed cholecystectomy for acute cholecystitis
Gallagher, T. K., Kelly, M. E., & Hoti, E. (2019) · BJS Open · doi:10.1002/bjs5.50120 · Cited by 28
Cost analysis in a randomized trial of early closure of a temporary ileostomy after rectal resection for cancer (EASY trial)
Park, J., Angenete, E., Bock, D., Marinez, A. C., Danielsen, A. K., Gehrman, J., Haglind, E., Jansen, J. E., Skullman, S., Wedin, A., et al. (2019) · Surgical Endoscopy · doi:10.1007/s00464-019-06732-y · Cited by 28
Cost-effectiveness of Mifepristone Pretreatment for the Medical Management of Nonviable Early Pregnancy
Nagendra, D., Koelper, N., Loza-Avalos, S. E., Sonalkar, S., Chen, M., Atrio, J., Schreiber, C. A., & Harvie, H. S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.1594 · Cited by 29
First-line oxygen therapy with high-flow in bronchiolitis is not cost saving for the health service
Gc, V. S., Franklin, D., Whitty, J. A., Dalziel, S. R., Babl, F. E., Schlapbach, L. J., Fraser, J. F., Craig, S. S., Neutze, J. M., Oakley, E. A., et al. (2020) · Archives of Disease in Childhood · doi:10.1136/archdischild-2019-318427 · Cited by 28
“20 For the base case analysis, Australian unit costs were applied to all resources used regardless of the trial site.”
Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT
Armstrong-Buisseret, L., Brittain, C., Kai, J., David, M. D., Watkins, J. A., Ozolins, M., Jackson, L., Abdali, Z., Hepburn, T., Griffiths, F., et al. (2022) · Health Technology Assessment · doi:10.3310/zzkh4176 · Cited by 28
Behavioural interventions to promote physical activity in a multiethnic population at high risk of diabetes: PROPELS three-arm RCT
Khunti, K., Griffin, S. J., Brennan, A., Dallosso, H. M., Davies, M. J., Eborall, H., Edwardson, C. L., Gray, L. J., Hardeman, W., Heathcote, L., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25770 · Cited by 33
Cost–Utility of Mindfulness-Based Stress Reduction for Fibromyalgia versus a Multicomponent Intervention and Usual Care: A 12-Month Randomized Controlled Trial (EUDAIMON Study)
Pérez‐Aranda, A., D’Amico, F., Feliu‐Soler, A., McCracken, L. M., Peñarrubia‐María, M. T., Andrés‐Rodríguez, L., Angarita‐Osorio, N., Knapp, M. R. J., García‐Campayo, J., & Luciano, J. V. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071068 · Cited by 29
“The present economic evaluation is reported according to the Consolidated Health Economic Evaluation Reporting Standards statement [45] (see Table S1) and follows the Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials [46].”
Method
Cost-effectiveness analysis of a randomized study of depression treatment options in primary care suggests stepped-care treatment may have economic benefits
Yan, C., Rittenbach, K., Souri, S., & Silverstone, P. H. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2223-3 · Cited by 31
“arm was applied for the analysis; this approach was utilized to avoid bias [31, 33].”
BackgroundMethodInfluential
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial
Retèl, V. P., Byng, D., Linn, S. C., Jóźwiak, K., Koffijberg, H., Rutgers, E. J. T., Cardoso, F., Piccart, M. J., Poncet, C., Veer, L. J. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.002 · Cited by 27
“This is the best available evidence to model recurrence and survival outcomes and their impact on cost-effectiveness with a high level of accuracy [6,28].”
BackgroundMethod
Evaluating the clinical benefit of brain-computer interfaces for control of a personal computer
Fry, A., Chan, A. H. W., Harel, N. Y., Spielman, L. A., Escalon, M. X., & Putrino, D. F. (2022) · Journal of Neural Engineering · doi:10.1088/1741-2552/ac60ca · Cited by 27
“Early and regular collection of economic data alongside effectiveness data has therefore been recommended to facilitate the translation of BCI prototypes to clinically available products [90].”
Cost‐utility and cost‐effectiveness analysis of a clinical medication review focused on personal goals in older persons with polypharmacy compared to usual care: Economic evaluation of the DREAMeR study
Verdoorn, S., van de Pol, J. M., Hövels, A. M., Kwint, H., Blom, J. W., Gussekloo, J., & Bouvy, M. L. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14421 · Cited by 27
“For studies to measure the cost-effectiveness of CMR, they should ideally measure HR-QoL and estimate quality-adjusted life years (QALYs).(20) However, many interventions that are performed during CMR are unlikely to improve HR-QoL for the short term (e.”
Background
The efficacy and cost‐effectiveness of a family‐based economic empowerment intervention (Suubi + Adherence) on suppression of HIV viral loads among adolescents living with HIV: results from a Cluster Randomized Controlled Trial in southern Uganda
Tozan, Y., Capasso, A., Sun, S., Neilands, T. B., Damulira, C., Namuwonge, F., Nakigozi, G. F., Mwebembezi, A., Mukasa, B., Bahar, O. S., et al. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25752 · Cited by 26
“We also conducted a sensitivity analysis [27] in which we computed the ICERs for a pessimistic scenario (high cost/low effectiveness) and an optimistic scenario (low cost/high effectiveness) for the intervention.”
Method
Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements
Mincarone, P., Leo, C. G., Sabina, S., Sarría‐Santamera, A., Taruscio, D., Serrano‐Aguilar, P., & Kanavos, P. G. (2017) · Public Health Genomics · doi:10.1159/000464100 · Cited by 26
A full Bayesian model to handle structural ones and missingness in economic evaluations from individual‐level data
Gabrio, A., Mason, A. J., & Baio, G. (2018) · Statistics in Medicine · doi:10.1002/sim.8045 · Cited by 26
“[27] Ramsey SD, Willke RJ, Glick H, et al.”
Background
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America
Raje, N., Roodman, G. D., Willenbacher, W., Shimizu, K., García-Sanz, R., Terpos, E., Kennedy, L., Sabatelli, L., Intorcia, M., & Hechmati, G. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1445634 · Cited by 25
Cost-utility analysis in orthopaedic trauma; what pays? A systematic review
Coyle, S., Kinsella, S., Lenehan, B. J., & Queally, J. M. (2018) · Injury · doi:10.1016/j.injury.2018.01.029 · Cited by 25
“Both methods ultimately generate a utility measure in the form of QALYs for use in a CUA [32].”
BackgroundMethodInfluential
Interpretation of trial-based economic evaluations of musculoskeletal physical therapy interventions
Miyamoto, G. C., Ben, Â. J., Bosmans, J. E., van Tulder, M. W., Lin, C. C., Cabral, C. M. N., & van Dongen, J. M. (2021) · Brazilian Journal of Physical Therapy · doi:10.1016/j.bjpt.2021.06.011 · Cited by 24
“44 In economic evaluations conducted alongside randomized controlled trials, patients are randomly allocated to one of the interventions and patient-level cost and effect data are gathered prospectively during follow-up.(32,34,36,41) It is also possible to conduct a trial-based economic evaluation alongside a non-rand…”
BackgroundMethodInfluential
Cost-utility of two minimally-invasive surgical techniques for operable oropharyngeal cancer: transoral robotic surgery versus transoral laser microsurgery
Parimbelli, E., Soldati, F., Duchoud, L., Armas, G., de Almeida, J. D., Broglie, M., Quaglini, S., & Simon, C. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-07149-x · Cited by 22
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-021-07460-7 · Cited by 26
Self-citation
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.2.146 · Cited by 27
Self-citation
Sustainable Financing of Innovative Therapies: A Review of Approaches
Hollis, A. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0416-x · Cited by 26
A hospital cost analysis of a fibrin sealant patch in soft tissue and hepatic surgical bleeding
Ferko, N. C., Corral, M., Hogan, A., Hollmann, S., Gangoli, G., Jamous, N., Batiller, J., & Kocharian, R. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s112762 · Cited by 25
Cost-effectiveness of interventions to control cardiovascular diseases and diabetes mellitus in South Asia: a systematic review
Singh, K., Chandrasekaran, A. M., Bhaumik, S., Chattopadhyay, K., Gamage, A. U., de Silva, P., Roy, A., Prabhakaran, D., & Tandon, N. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017809 · Cited by 25
Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT)
Basulaiman, B. M., Awan, A. A., Fergusson, D. A., Vandermeer, L., Arnaout, A., Hilton, J. F., Hutton, B., Joy, A. A., Robinson, A. G., Califaretti, N., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05274-0 · Cited by 25
The long and winding road to happiness: A randomized controlled trial and cost-effectiveness analysis of a positive psychology intervention for lonely people with health problems and a low socio-economic status
Weiss, L., Voshaar, M. A. H. O., Bohlmeijer, E. T., & Westerhof, G. J. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01416-x · Cited by 27
Cost-Effectiveness of Domiciliary High Flow Nasal Cannula Treatment in COPD Patients with Chronic Respiratory Failure
Sørensen, S. S., Storgaard, L. H., & Weinreich, U. M. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s312523 · Cited by 24
“The analysis was conducted as a within-trial analysis and was performed in accordance with international guidelines.(26,27) The time horizon of the CUA followed that of the clinical trial, ie 12 months; hence, no discounting was performed.”
Method
Cost, Value, and Financial Hardship in Cancer Care: Implications for Pediatric Oncology
Parsons, S. K., Castellino, S. M., & Yabroff, K. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200359 · Cited by 26
Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments
Bojke, L., Schmitt, L. H. M., Lomas, J. R. S., Richardson, G. A., & Weatherly, H. L. A. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15112459 · Cited by 24
“more generic g idance relating to the conduct of single study (usually trial-based) [5] and model-based economic evaluations [6].”
Background
The cost of Medicare-funded medical and pharmaceutical services for mental disorders in children and adolescents in Australia
Le, L. K., Shih, S. T. F., Richards‐Jones, S., Chatterton, M. L., Engel, L., Stevenson, C., Lawrence, D. M., Pépin, G., & Mihalopoulos, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249902 · Cited by 24
“As recommended by the International Society for Pharmacoeconomics and Outcome Research guidelines, a gamma error distribution with a logarithmic link function was used in the GLM to model the skewed distribution of the data [20].”
Method
Cost‐effectiveness analysis of a multi‐dimensional intervention to reduce inappropriate antibiotic prescribing for children with upper respiratory tract infections in China
Zhang, Z., Dawkins, B., Hicks, J. P., Walley, J. D., Hulme, C. T., Elsey, H., Deng, S., Lin, M., Zeng, J., & Wei, X. (2018) · Tropical Medicine & International Health · doi:10.1111/tmi.13132 · Cited by 24
“The level of sampling uncertainty around the ICER was determined using a non-parametric bootstrap, specifying clusters defined by the township hospital and strata defined by the county in which the hospital was located, to generate 10 000 estimates of incremental cost and benefits which were plotted on the cost-effect…”
Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial
McMeekin, N., Geue, C., Briggs, A. H., Rombach, I., Li, H. K., Bejon, P., McNally, M., Atkins, B. L., Ferguson, J. Y., Scarborough, M., et al. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15314.4 · Cited by 24
Self-citation
Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States
Carlson, J. J., FOOS, V., Kasle, A., Mugwagwa, T., Draica, F., Wiemken, T. L., Nguyen, J. L., Cha-Silva, A. S., Migliaccio–Walle, K., & Dzingina, M. (2023) · Value in Health · doi:10.1016/j.jval.2023.11.003 · Cited by 24
A cost-effectiveness analysis of early detection and bundled treatment of postpartum hemorrhage alongside the E-MOTIVE trial
Williams, E. V., Goranitis, I., Oppong, R., Perry, S. J., Devall, A., Martín, J., Mammoliti, K., Beeson, L. E., Sindhu, K. N., Galadanci, H. S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03069-5 · Cited by 23
“Given that composite outcomes are generally inadequate for economic evaluation due to varying component importance, disaggregation is recommended 16 .”
An overview of systematic reviews of economic evaluations of pharmacy-based public health interventions: addressing methodological challenges
Costa, S., Cary, M., Helling, D. K., Pereira, J., & Mateus, C. (2019) · Systematic Reviews · doi:10.1186/s13643-019-1177-3 · Cited by 24
Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery
Glickman, A., Brennecke, A., Tayebnejad, A., Matsuo, K., Guntupalli, S. R., & Sheeder, J. L. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.096 · Cited by 23
Barriers and facilitators to conducting economic evaluation studies of Gulf Cooperation Council (GCC) countries: a survey of researchers
Almazrou, S. H., AlAujan, S. S., & Al-Aqeel, S. (2021) · Health Research Policy and Systems · doi:10.1186/s12961-021-00721-1 · Cited by 27
“DIRUM is also recommended by the International Society for Pharmacoeconomics and Outcomes Research to collect healthcare resource use data [47].”
Method
Evaluation of a complex intervention (Engager) for prisoners with common mental health problems, near to and after release: study protocol for a randomised controlled trial
Kirkpatrick, T., Lennox, C., Taylor, R. S., Anderson, R., Maguire, M., Haddad, M., Michie, S., Owens, C. V., Durcan, G., Stirzaker, A., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017931 · Cited by 23
“conducting trial-based economic evaluation.(58) Consistent with the analytical approach used in the statistical analysis of the effectiveness outcomes of the RCT where possible; the cost-effectiveness analysis will be reported in accordance with the Consolidated Health Economic Evaluation Reporting Standards.”
Economic evaluation of a phase III international randomised controlled trial of very early mobilisation after stroke (AVERT)
Gao, L., Sheppard, L., Wu, O., Churilov, L. P., Mohebbi, M., Collier, J. M., Bernhardt, J. A., Ellery, F., Dewey, H. M., & Moodie, M. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026230 · Cited by 23
“sensitivity analyses To investigate the impact of using country-specific costs, a country dummy variable was added to the GLM analysis to adjust for country effect.(25) Subgroup analysis on the basis of individual countries were also conducted to explore the difference in costs and benefits across countries.”
BackgroundMethod
Mapping analysis to predict EQ-5D-5 L utility values based on the Oxford Hip Score (OHS) and Oxford Knee Score (OKS) questionnaires in the Spanish population suffering from lower limb osteoarthritis
Martín‐Fernández, J., Morey-Montalvo, M., Tomás-García, N., Martín-Ramos, E., Muñoz-García, J. C., Polentinos-Castro, E., Rodríguez-Martínez, G., Arenaza, J. C., García‐Pérez, L., Magdalena-Armas, L., et al. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01435-8 · Cited by 24
“Health state preference scores can be transformed into quality-adjusted life years (QALYs), which are an outcome metric for health benefit used in many health economic evaluations [2].”
Background
Guided Internet-Based Cognitive Behavioral Therapy for Insomnia: Health-Economic Evaluation From the Societal and Public Health Care Perspective Alongside a Randomized Controlled Trial
Buntrock, C., Lehr, D., Smit, F., Horvath, H., Berking, M., Spiegelhalder, K., Riper, H. M., & Ebert, D. D. (2021) · Journal of Medical Internet Research · doi:10.2196/25609 · Cited by 22
Cost–Benefit Analysis of the COPE Program for Persons Living With Dementia: Toward a Payment Model
Pizzi, L. T., Jutkowitz, E., Prioli, K. M., Lu, E., Babcock, Z. R., McAbee‐Sevick, H., Wakefield, D. B., Robison, J. T., Molony, S. L., Piersol, C. V., et al. (2021) · Innovation in Aging · doi:10.1093/geroni/igab042 · Cited by 22
“This is common for cost assessments conducted alongside clinical trials (45).”
Background
Economic evaluation of healthcare interventions: old and new directions: Table 1:
Gray, A. M., & Wilkinson, T. (2016) · Oxford Review of Economic Policy · doi:10.1093/oxrep/grv020 · Cited by 22
Cost‐Effectiveness Analysis of Second‐Line Chemotherapy Agents for Advanced Gastric Cancer
Lam, S. W., Wai, M., Lau, J. E., McNamara, M. J., Earl, M. A., & Udeh, B. L. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1870 · Cited by 22
“Both future costs and clinical outcomes were discounted at 3% annually.(11) Half-cycle correction was used.”
Method
Cost-effectiveness Analysis of Stereotactic Radiosurgery Alone Versus Stereotactic Radiosurgery with Upfront Whole Brain Radiation Therapy for Brain Metastases
Kim, H., Rajagopalan, M. S., Beriwal, S., & Smith, K. J. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.05.001 · Cited by 22
A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT)
Irvine, A. D., Jones, A. P., Beattie, P. E., Baron, S. E., Browne, F., Ashoor, F., O’Neill, L. M., Rosala‐Hallas, A., Sach, T., Spowart, C., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16717 · Cited by 22
Cost-effectiveness of PoNDER health visitor training for mothers at lower risk of depression: findings on prevention of postnatal depression from a cluster-randomised controlled trial
Henderson, C., Dixon, S., Bauer, A., Knapp, M., Morrell, C. J., Slade, P., Walters, S. J., & Brugha, T. (2019) · Psychological Medicine · doi:10.1017/s0033291718001940 · Cited by 21
“Our cost-effectiveness analysis adopted methods consistent with good practice guidelines (Ramsey et al., 2015) and employed methods relevant to clustered data, but the choice of analytical model can influence results (Mantopoulos et al., 2016) and so is a source of methodological uncertainty.”
Method
Cost-Effectiveness of Radiofrequency Denervation for Patients With Chronic Low Back Pain: The MINT Randomized Clinical Trials
Maas, E. T., Juch, J. N. S., Ostelo, R., Groeneweg, G., Kallewaard, J. W., Koes, B. W., Verhagen, A. P., van Dongen, J. M., van Tulder, M. W., & Huygen, F. J. P. M. (2020) · Value in Health · doi:10.1016/j.jval.2019.12.009 · Cited by 22
“Medication 351 (47) 196 (50) 155 (17-281) 156 (5-300)”
Background
A pilot randomised controlled trial of dressing and securement methods to prevent arterial catheter failure in intensive care
Larsen, E. N., Corley, A., Mitchell, M. L., Lye, I., Powell, M., Tom, S., Mihala, G., Ullman, A. J., Gibson, V., Marsh, N. M., et al. (2020) · Australian Critical Care · doi:10.1016/j.aucc.2020.05.004 · Cited by 21
Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT
Hykin, P. G., Prevost, A. T., Sivaprasad, S., Vasconcelos, J. C., Murphy, C., Kelly, J., Ramu, J., Alshreef, A., Flight, L., Pennington, B., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25380 · Cited by 21
Economic evaluations and costing studies of lung transplantation: A scoping review
Peel, J. K., Keshavjee, S. H., Krahn, M. D., & Sander, B. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.08.007 · Cited by 22
“Cost‐effectiveness of ACL treatment is dependent on age and activity level: a systematic review”
Deviandri, R., van der Veen, H. C., Lubis, A. M. T., van den Akker‐Scheek, I., & Postma, M. J. (2022) · Knee Surgery Sports Traumatology Arthroscopy · doi:10.1007/s00167-022-07087-z · Cited by 20
The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials
Clayton, G. L., Smith, I. L., Higgins, J. P. T., Mihaylova, B., Thorpe, B., Cicero, R., Lokuge, K., Forman, J., Tierney, J. F., White, I. R., et al. (2017) · Trials · doi:10.1186/s13063-017-1955-y · Cited by 22
“Trial-based economic analysis are sometimes secondary to the clinical aspect rather than being fully integrated within a trial design [29] meaning that the use of decision models and VoI analyses to inform trial design is limited.”
BackgroundMethod
Low-intensity pulsed ultrasound for treatment of tibial fractures
Tarride, J., Hopkins, R. B., Blackhouse, G., Burke, N., Bhandari, M., Johal, H. S., Guyatt, G. H., & Busse, J. W. (2017) · The Bone & Joint Journal · doi:10.1302/0301-620x.99b11.bjj-2017-0737 · Cited by 22
Clinic Versus Online Social Network–Delivered Lifestyle Interventions: Protocol for the Get Social Noninferiority Randomized Controlled Trial
Wang, M. L., Waring, M. E., Jake‐Schoffman, D. E., Oleski, J. L., Michaels, Z., Goetz, J. M., Lemon, S. C., Ma, Y., & Pagoto, S. (2017) · JMIR Research Protocols · doi:10.2196/resprot.8068 · Cited by 21
“…systematically track costs associated with delivery of both intervention conditions, capturing information on the costs that would be required to implement each intervention in practice (ie, outside the research context), including administrative, interventionists, and participant costs [36-38].”
Cost-Effectiveness of Erythropoietin in Traumatic Brain Injury: A Multinational Trial-Based Economic Analysis
Knott, R. J., Harris, A., Higgins, A. M., Nichol, A., French, C., Little, L., Haddad, S. H., Presneill, J., Arabi, Y. M., Bailey, M., et al. (2019) · Journal of Neurotrauma · doi:10.1089/neu.2018.6229 · Cited by 22
“32 This meant that considerable uncertainty was observed in the trial-wide estimates for costs, and region-speciﬁc estimates for both Estimates calculated using method of recycled predictions from generalised linear models (costs), and Weibull regressions and multiple regressions (QALYs); 95%…”
Influential
Supporting self-care for eczema: protocol for two randomised controlled trials of ECO (Eczema Care Online) interventions for young people and parents/carers
Müller, I., Stuart, B. L., Sach, T., Hooper, J., Wilczynska, S., Steele, M., Greenwell, K., Sivyer, K., Yardley, L., Williams, H. C., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045583 · Cited by 21
“41 42 Missing data will be dealt with in line with the approach taken in the main clinical statistical analysis, with sensitivity analysis undertaken to test the impact of approach if missing data is a particular problem.”
Cost-effectiveness of extracorporeal cardiopulmonary resuscitation vs. conventional cardiopulmonary resuscitation in out-of-hospital cardiac arrest: a pre-planned, trial-based economic evaluation
Delnoij, T., Suverein, M. M., Essers, B. A. B., Hermanides, R. C., Otterspoor, L., Kraemer, C. V. E., Vlaar, A. P. J., van der Heijden, J., Scholten, E., den Uil, C. A., et al. (2024) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuae050 · Cited by 20
Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers?
Perry, L. M., Bateni, S. B., Bold, R. J., & Hoch, J. S. (2021) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2021.02.014 · Cited by 20
Cost-effectiveness of a Multicomponent Intervention for Hypertension Control in Low-Income Settings in Argentina
Zhang, Y., Yin, L., Mills, K. T., Chen, J., He, J., Palacios, A., Pichón-Rivière, A., Irazola, V. E., Augustovski, F., & Shi, L. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.22559 · Cited by 20
Self-citation
Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms
Abdel‐Fattah, M., Chapple, C. R., Guerrero, K. L., Dixon, S., Cotterill, N., Ward, K., Hashim, H., Monga, A. K., Brown, K., Drake, M. J., et al. (2021) · Trials · doi:10.1186/s13063-021-05661-3 · Cited by 20
“The within trial analysis will follow the best practice guidelines [40].”
Method
Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs
Velikova, G., Absolom, K. L., Hewison, J., Holch, P., Warrington, L., AVERY, K. N. L., Richards, H. S., Blazeby, J. M., Dawkins, B., Hulme, C. T., et al. (2022) · Programme Grants for Applied Research · doi:10.3310/fdde8516 · Cited by 21
Reporting and Analysis of Trial-Based Cost-Effectiveness Evaluations in Obstetrics and Gynaecology
Alili, M. E., van Dongen, J. M., Huirne, J. A. F., van Tulder, M. W., & Bosmans, J. E. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0531-3 · Cited by 20
“Handling of missing data: Multiple imputation (MI) is currently considered the most appropriate method for dealing with missing cost data [13, 14], while maximum likelihood approaches (e.”
Method
Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT
Webb, N. J. A., Woolley, R. L., Lambe, T., Frew, E. J., Brettell, E. A., Barsoum, E., Trompeter, R. S., Cummins, C., Wheatley, K., & Ives, N. J. (2019) · Health Technology Assessment · doi:10.3310/hta23260 · Cited by 20
Robot-assisted Versus Open Radical Cystectomy in Bladder Cancer: An Economic Evaluation Alongside a Multicentre Comparative Effectiveness Study
Michels, C. T. J., Wijburg, C. J., Hannink, G., Witjes, J. A., Rovers, M. M., Grutters, J. P. C., Helder, S., Venderbosch, G. W. J., Calsbeek, H., Wijburg, C. J., et al. (2021) · European Urology Focus · doi:10.1016/j.euf.2021.06.004 · Cited by 19
Short Term Economic Evaluation of the Digital Platform “Support, Monitoring and Reminder Technology for Mild Dementia” (SMART4MD) for People with Mild Cognitive Impairment and their Informal Caregivers
Ghani, Z., Saha, S., Jarl, J., Andersson, M., Berglund, J. S., & Anderberg, P. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215013 · Cited by 19
Diretriz metodológica para estudos de avaliação econômica de tecnologias em saúde no Brasil
Ribeiro, R. A., Neyeloff, J. L., Itria, A., Santos, V. C. C., Vianna, C. M. D. M., da Silva, E. N., Elias, F. T. S., Wichmann, R. M., Souza, K. M., Cruz, L. N., et al. (2016) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v8.n3.p174-184 · Cited by 19

Authors: Ramsey, S. D., Willke, R. J., Glick, H., Reed, S. D., Augustovski, F., Jonsson, B., Briggs, A., & Sullivan, S. D.
Affiliations: University of Washington (US)
Pfizer (United States) (US)
University of Pennsylvania (US)
Duke University (US)
Universidad de Buenos Aires (AR)
University of Glasgow (GB)
Corresponding author: Ramsey, Scott D.
ORCID: Ramsey, Scott D.
Willke, Richard J.
Reed, Shelby D.
Augustovski, Federico
Briggs, Andrew
Sullivan, Sean D.
Venue: Value in Health
Publisher: Elsevier BV
Published: 2015-03
Volume: 18
Issue: 2
Pages: 161-172
ISSN: 1098-3015 (ISSN-L)
DOI: 10.1016/j.jval.2015.02.001
OpenAlex: W2139814250
Cited by: 811
References: 184
Citations by year: 2026: 58 · 2025: 75 · 2024: 90 · 2023: 80 · 2022: 100 · 2021: 103 · 2020: 88 · 2019: 65 · 2018: 50 · 2017: 57 · 2016: 37 · 2015: 6
FWCI: 17.59
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
Locations: Value in Health (publishedVersion)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Topics: Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Environmental Valuation
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords: cost-effectiveness analysis, clinical trials, economic evaluation, trial design, health care utilization, health utility, intention-to-treat analysis, subgroup analysis, uncertainty characterization, reporting guidelines, reimbursement decisions, healthcare resource allocation
MeSH terms: Cost-Benefit Analysis, Health Policy, Health Services Research, Humans, Randomized Controlled Trials as Topic, Advisory Committees, Research Report

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks